Stoke Therapeutics logo

Stoke Therapeutics

STOK | NASDAQ
Chart Builder DCF Calculator
$26.63
-$0.05 (-0.19%)
At close: Nov 16, 2026, 4:00 PM ET
$26.63
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-0.19%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
51.8
+1.0 pts
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #247/1021 (Top 24%)

Key Statistics

Market Data

Market Cap $1.74B
1D Range
26.37 27.50
52W Range
22.50 38.35

Valuation (TTM)

PE -7.03
PB 4.94
EV/EBITDA -5.87

Valuation (NTM)

Forward PE N/A
Forward PEG 0.00
Price Target $50.50
Loading financial charts...

Profile

Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundament...

Sector Healthcare
Industry Biotechnology
Employees 170
IPO Date Jun 19, 2019
Fiscal Year January - December

Latest News

Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript

18 days ago · seekingalpha.com

Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript
Stoke Therapeutics Q3 Earnings Call Highlights

18 days ago · marketbeat.com

Stoke Therapeutics Q3 Earnings Call Highlights
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates

18 days ago · zacks.com

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
Stoke Therapeutics: The Market Misread A Key FDA Win

28 days ago · seekingalpha.com

Stoke Therapeutics: The Market Misread A Key FDA Win
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

1 month ago · businesswire.com

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

2 months ago · businesswire.com

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t

2 months ago · gurufocus.com

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results

3 months ago · benzinga.com

These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results
Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript

3 months ago · seekingalpha.com

Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

4 months ago · zacks.com

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Earnings

Latest Earnings
Oct 29, 2026
EPS
-$1.08
Miss -16.24%
REV
$11.26M
Beat +37.06%
Next Earnings
Mar 15, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
7
Consensus
Buy
Price Target
$50.50
Upside
+89.64%
Buy (7)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.